EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Redefining pancreatic cancer management with tumor-agnostic precision medicine

Neha K Reddy, Vivek Subbiah iD

Carcinogenesis · 22.11.2024 · 45 (11) · 836-844

DOI: 10.1093/carcin/bgae066 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Carcinogenesis, online erschienen am 08.11.2024. Verfasst von Neha K Reddy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, 420 E Superior Street, Chicago, IL …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Precision Medicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy. However, there exist other actionable alterations, such as BRCA1/2 mutations and fusion genes (BRAF, FGFR2, RET, NTRK, NRG1, and ALK), which present potential targets for therapy. Notably, tumor-agnostic drugs have demonstrated efficacy in specific subsets of pancreatic cancer patients who harbor these genetic alterations. Despite the rarity of NTRK fusions in pancreatic cancer, larotrectinib and entrectinib have exhibited effectiveness in NTRK fusion-positive pancreatic cancers. Additionally, repotrectinib, a next-generation NTRK inhibitor, has shown promising activity in NTRK positive pancreatic cancer patients who have developed acquired resistance to previous NTRK inhibitors. Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have proven to be effective in dMMR/MSI-H pancreatic cancers. Moreover, targeted therapies for BRAF V600, RET fusions, and HER2/neu overexpression have displayed promising results in specific subsets of pancreatic cancer patients. Emerging targets like NRG fusions, FGFR2 fusions, TP53 mutations, and KRAS G12C mutations present potential avenues for targeted therapy. Tumor-agnostic therapies have the potential to revolutionize pancreatic cancer treatment by focusing on specific genetic alterations. It is crucial to continue implementing comprehensive screening strategies that encompass the ability to detect all these tumor-agnostic biomarkers. This will be essential in identifying pancreatic cancer patients who may benefit from these therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsPrecision MedicineHumansBiomarkers, TumorMutationMolecular Targeted TherapyOncogene Proteins, Fusion

Stichwörter der Autor:innen

BRAFNTRKRETprecision oncologytissue-agnostictumor-agnostic

Substanzen

Biomarkers, TumorOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Oncology, Northwestern University Feinberg School of Medicine, 420 E Superior Street, Chicago, IL 60611, United States.
  • Early-Phase Drug Development, Sarah Cannon Research Institute, 335 24th Avenue North Suite 300, Nashville, TN 37203, United States.

ORCID-Profile: Vivek Subbiah

Zitieren

APA

Reddy, N. K., & Subbiah, V. (2024). Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis, 45(11), 836-844. https://doi.org/10.1093/carcin/bgae066

Vancouver

Reddy NK, Subbiah V. Redefining pancreatic cancer management with tumor-agnostic precision medicine. Carcinogenesis. 2024;45(11):836-844. doi:10.1093/carcin/bgae066

BibTeX
@article{Reddy2024,
  author = {Reddy, Neha K and Subbiah, Vivek},
  title = {Redefining pancreatic cancer management with tumor-agnostic precision medicine},
  journal = {Carcinogenesis},
  year = {2024},
  volume = {45},
  number = {11},
  pages = {836--844},
  doi = {10.1093/carcin/bgae066}
}
Kostenlos starten →